U.S. Markets open in 8 hrs.

Rosetta Genomics Ltd. (ROSG)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.805-0.135 (-6.959%)
At close: 3:59PM EDT
People also watch
  • gedy for ascary scary crash crashbelow 1.50 be veryvery af money run run to the exit exit door get ouout beterbesafe than sorry
  • Has anyone tried actually suing this company before, just curious? I'm in on small shares but jeez I have never, ever seen this thing going up. Where are the lawsuits?
  • When, if ever, has a management action resulted in a higher stock price? It seems to me that any rise in share price is an invitation by management to bring it back down.
  • When the pumpers came in last couple of weeks, I knew that this was going to take a chtz! Shorts love this stock! Ken Berlin will be looking over his shoulder for the rest of his life, FBI, etc; all for greed!
  • Kenny lie on May 21st:

    "Since announcing our strategic focus on RosettaGX Reveal™ (Reveal) and the exploration of alternatives for our PersonalizeDx business at the start of this month, we have received inquiries from multiple parties expressing interest in acquiring our PersonalizeDx business," said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "In parallel, the current market conditions for selling equity are not favorable to microcap companies, and we believe the terms proposed to us by potential investors are not in the best interest of our shareholders. As such, we are suspending plans to raise capital under the Form F-1 registration statement until further notice, and instead will continue to explore other means to improve our cash position. The potential sale of our PersonalizeDx business would have the benefit of bringing in non-dilutive cash as well as reducing our cash burn rate by approximately 20%. We also are pursuing opportunities to monetize certain IP assets, which represent another potential source of non-dilutive cash, and are exploring several other avenues for raising capital."
  • huge dillution back on..maybe gets done under 1. with warrants like 7m new shares....can you say reverse split
  • Told u so!
  • Rosetta Genomics files for 16.358M offering of Class A, Class B units, Warrants
  • 10% of market cap. Last I read, Ken's annual salary is $500K. That's over 10% of market cap. Imagine if any other CEO were paid that much. #$%$ company with stinking leadership.
  • I understand the CEO is in Israel trying to avoid SEC charges and lawsuits against him and his cronies. There's got to be some way to get the guy since it's listed on the NASDAQ.. America can still go after foreign nationals, I am assuming he is American or is he Isreali?
  • what a liar what happened to multiple parties interested in buying PersonalizedDx not two months ago? Glad I got out with 40% profits but this guy is totally full of it.
  • trash. Took profits. Kenny totally lied. Too bad. I believe in Reveal but share count is increasing exponentially now.
  • PersonalizeDx business will not even fetch Ken's 2 months worth of salary
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets


    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.


    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • What a cheat! So what? Hold again?
  • Reveal is real. I'm a recent investor to ROSG with an average buy-in price of around $2.85 and now have substantial ownership of ROSG.. Both my father and my sister had thyroid surgery because their lab tests came back as "indeterminate". Fortunately both cases were benign ! The point being that Reveal could likely have saved $10,000's to the insurance company.
    This product alone is worth a $40+ million valuation now that its approved and marketed, not to mention all the other IP. ROSG at these price levels is a crazy bargain and someone has figured it out and is accumulating. Last chance to buy at these levels in my opinion!!!
  • Kenny selling shares before ER?
  • didnt lie...just spent to much cash. cant sell personal dx. giving away 80 percent if the company for 3 to 4 million bucks. will get done under 1 dollar
  • Michael- We had 7.6 million in January. We should run out of cash by aug. 15 ( assuming same burn rate like last year )
    Hopefullly with some reduction in staff and reveal revenue the fund could last till sept 30.

    If personalized DX is sold it would buy another 6 weeks

    So Mr. Berlin will have some good announcement in July and he will follow that up with ATM. We need to get out before ATM.
  • I predict we will hear about the sale of PersonalizedDx in July or August and it will bring in a lot more money than many of you are expecting - giving the company some very solid non-dilutive funding. I believe there are quite a few entities out there bidding for PersonalizedDex.